Guardant Health (GH) and Zephyr AI announced a strategic partnership to insights that support biopharmaceutical innovation. This collaboration will combine multimodal molecular data and AI/ML technology from both companies driving advancement of novel cancer biomarkers for drug development, targeted therapies selection, and response monitoring.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health to present data on blood-based testing in cancer screening
- Guardant Health price target raised to $90 from $60 at Piper Sandler
- Tempus AI price target raised to $105 from $70 at Piper Sandler
- EXAS, GH, PLTR, SOFI: Cathie Wood Invests $5.5M in Exact Sciences, Trims Stakes in Guardant, Palantir, SoFi, and Other Big Names
- Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role